C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
C4 Therapeutics, Inc. (CCCC)
NASDAQ:AMEX Investor Relations:
ir.chinacache.com
Company Research
Source: GlobeNewswire
Cemsidomide Phase 1/2 Trial in Multiple Myeloma and non-Hodgkin’s Lymphoma Continues to Progress: Data from Both Indications to be Presented at the 66th American Society of Hematology (ASH) Annual Meeting in San Diego, CA Initial Monotherapy CFT1946 Phase 1 Data Demonstrated Well-Tolerated Safety Profile and Early Evidence of Anti-tumor Activity; Phase 1/2 Trial Continues to Progress with Multiple Data Readouts Expected in 2025 Appointed Paige Mahaney, Ph.D. as Chief Scientific Officer Bringing More than 25 Years of Pharmaceutical and Biotech Experience Cash, Cash Equivalents and Marketable Securities of $284.4 million as of September 30, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, reported financial results today for the third quarter ended September 30, 2024, as wel
Show less
Read more
Impact Snapshot
Event Time:
CCCC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CCCC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CCCC alerts
High impacting C4 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CCCC
News
- Targeted Protein Degradation Industry Forecast to Reach $4.37 Billion by 2034: PROTACs Lead the Charge with Promising Innovations in Oncology [Yahoo! Finance]Yahoo! Finance
- C4 Therapeutics, Inc. (NASDAQ: CCCC) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $12.00 price target on the stock, up previously from $8.00.MarketBeat
- C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 DegraderGlobeNewswire
- Comprehensive Synovial Sarcoma Pipeline Landscape Report for 2024: In-depth Analysis of 20+ Pipeline Drugs and 15+ Companies [Yahoo! Finance]Yahoo! Finance
- C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors [Yahoo! Finance]Yahoo! Finance
CCCC
Earnings
- 5/8/24 - In-Line
CCCC
Sec Filings
- 12/9/24 - Form 8-K
- 11/21/24 - Form 4
- 11/21/24 - Form 3
- CCCC's page on the SEC website